Clinical trial
Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT…
NCT00158691 · Groupe Oncologie Radiotherapie Tete et Cou, Other · Completed
Key facts
| NCT number | NCT00158691 |
|---|---|
| Title | Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas |
| Official title | A Randomized Phase III Study Comparing Intravenous Versus Subcutaneous Administration of Amifostine in Prevention of Xerostomia for Patients Receiving Radiotherapy for Head and Neck Carcinomas |
| Lead sponsor | Groupe Oncologie Radiotherapie Tete et Cou, Other |
| Collaborators | Schering-Plough Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Ethyol |
| Enrollment | 296 |
| Start date | Mar 1, 2001 |
| First posted | Sep 12, 2005 |
| Last update posted | Sep 12, 2005 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: